Insider Buying: Lexicon Pharmaceuticals, Inc. (LXRX) Director Purchases 145,680 Shares of Stock

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Director Public Equities L.P. Invus bought 145,680 shares of the firm’s stock in a transaction on Friday, November 10th. The stock was acquired at an average cost of $9.74 per share, for a total transaction of $1,418,923.20. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Public Equities L.P. Invus also recently made the following trade(s):

  • On Tuesday, November 14th, Public Equities L.P. Invus bought 575,946 shares of Lexicon Pharmaceuticals stock. The stock was acquired at an average cost of $9.64 per share, for a total transaction of $5,552,119.44.

Lexicon Pharmaceuticals, Inc. (NASDAQ LXRX) traded down $0.08 during trading on Tuesday, reaching $9.73. 888,000 shares of the company traded hands, compared to its average volume of 804,741. Lexicon Pharmaceuticals, Inc. has a 12-month low of $8.07 and a 12-month high of $18.00. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.66 and a quick ratio of 1.65.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.36) by $0.07. Lexicon Pharmaceuticals had a negative net margin of 165.69% and a negative return on equity of 111.68%. The firm had revenue of $26.94 million during the quarter, compared to the consensus estimate of $27.97 million. During the same quarter last year, the firm earned ($0.35) EPS. The firm’s revenue for the quarter was down 2.8% on a year-over-year basis. sell-side analysts expect that Lexicon Pharmaceuticals, Inc. will post -1.45 EPS for the current year.

TRADEMARK VIOLATION WARNING: “Insider Buying: Lexicon Pharmaceuticals, Inc. (LXRX) Director Purchases 145,680 Shares of Stock” was reported by Markets Daily and is the sole property of of Markets Daily. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The legal version of this article can be read at https://www.themarketsdaily.com/2017/11/15/insider-buying-lexicon-pharmaceuticals-inc-lxrx-director-purchases-145680-shares-of-stock.html.

A number of institutional investors have recently bought and sold shares of the stock. FMR LLC increased its holdings in Lexicon Pharmaceuticals by 0.9% in the 2nd quarter. FMR LLC now owns 15,785,280 shares of the biopharmaceutical company’s stock valued at $259,668,000 after purchasing an additional 137,421 shares during the last quarter. Vanguard Group Inc. boosted its position in Lexicon Pharmaceuticals by 16.3% in the 1st quarter. Vanguard Group Inc. now owns 4,168,301 shares of the biopharmaceutical company’s stock valued at $59,773,000 after buying an additional 585,222 shares during the period. USS Investment Management Ltd purchased a new position in Lexicon Pharmaceuticals in the 2nd quarter valued at approximately $57,705,000. Eagle Asset Management Inc. boosted its position in Lexicon Pharmaceuticals by 0.3% in the 2nd quarter. Eagle Asset Management Inc. now owns 2,861,065 shares of the biopharmaceutical company’s stock valued at $47,064,000 after buying an additional 8,756 shares during the period. Finally, State Street Corp boosted its position in Lexicon Pharmaceuticals by 19.9% in the 2nd quarter. State Street Corp now owns 1,967,255 shares of the biopharmaceutical company’s stock valued at $32,363,000 after buying an additional 326,088 shares during the period.

A number of research analysts have weighed in on LXRX shares. Needham & Company LLC reissued a “buy” rating and issued a $21.00 target price on shares of Lexicon Pharmaceuticals in a research note on Sunday, September 17th. Zacks Investment Research upgraded shares of Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, July 18th. Wedbush restated an “outperform” rating on shares of Lexicon Pharmaceuticals in a report on Thursday, October 5th. BidaskClub downgraded shares of Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, August 2nd. Finally, Cowen and Company restated a “hold” rating on shares of Lexicon Pharmaceuticals in a report on Tuesday, August 1st. One analyst has rated the stock with a sell rating, three have issued a hold rating and four have assigned a buy rating to the company’s stock. Lexicon Pharmaceuticals has an average rating of “Hold” and a consensus target price of $28.75.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development.

Receive News & Ratings for Lexicon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply